| UniProt ID | APC4_HUMAN | |
|---|---|---|
| UniProt AC | Q9UJX5 | |
| Protein Name | Anaphase-promoting complex subunit 4 | |
| Gene Name | ANAPC4 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 808 | |
| Subcellular Localization | ||
| Protein Description | Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains.. | |
| Protein Sequence | MLRFPTCFPSFRVVGEKQLPQEIIFLVWSPKRDLIALANTAGEVLLHRLASFHRVWSFPPNENTGKEVTCLAWRPDGKLLAFALADTKKIVLCDVEKPESLHSFSVEAPVSCMHWMEVTVESSVLTSFYNAEDESNLLLPKLPTLPKNYSNTSKIFSEENSDEIIKLLGDVRLNILVLGGSSGFIELYAYGMFKIARVTGIAGTCLALCLSSDLKSLSVVTEVSTNGASEVSYFQLETNLLYSFLPEVTRMARKFTHISALLQYINLSLTCMCEAWEEILMQMDSRLTKFVQEKNTTTSVQDEFMHLLLWGKASAELQTLLMNQLTVKGLKKLGQSIESSYSSIQKLVISHLQSGSESLLYHLSELKGMASWKQKYEPLGLDAAGIEEAITAVGSFILKANELLQVIDSSMKNFKAFFRWLYVAMLRMTEDHVLPELNKMTQKDITFVAEFLTEHFNEAPDLYNRKGKYFNVERVGQYLKDEDDDLVSPPNTEGNQWYDFLQNSSHLKESPLLFPYYPRKSLHFVKRRMENIIDQCLQKPADVIGKSMNQAICIPLYRDTRSEDSTRRLFKFPFLWNNKTSNLHYLLFTILEDSLYKMCILRRHTDISQSVSNGLIAIKFGSFTYATTEKVRRSIYSCLDAQFYDDETVTVVLKDTVGREGRDRLLVQLPLSLVYNSEDSAEYQFTGTYSTRLDEQCSAIPTRTMHFEKHWRLLESMKAQYVAGNGFRKVSCVLSSNLRHVRVFEMDIDDEWELDESSDEEEEASNKPVKIKEEVLSESEAENQQAGAAALAPEIVIKVEKLDPELDS | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 3 | Methylation | -----MLRFPTCFPS -----CCCCCCCCCC | 33.91 | - | |
| 29 | Phosphorylation | EIIFLVWSPKRDLIA EEEEEEECCHHHHHH | 17.05 | 24719451 | |
| 87 | Phosphorylation | LAFALADTKKIVLCD EEEEEECCCEEEEEE | 28.73 | 21406692 | |
| 89 | Ubiquitination | FALADTKKIVLCDVE EEEECCCEEEEEECC | 39.89 | - | |
| 147 | Ubiquitination | PKLPTLPKNYSNTSK CCCCCCCCCCCCHHH | 72.18 | - | |
| 147 | Ubiquitination | PKLPTLPKNYSNTSK CCCCCCCCCCCCHHH | 72.18 | - | |
| 154 | Ubiquitination | KNYSNTSKIFSEENS CCCCCHHHHCCCCCH | 45.81 | - | |
| 154 | Ubiquitination | KNYSNTSKIFSEENS CCCCCHHHHCCCCCH | 45.81 | - | |
| 199 | Phosphorylation | MFKIARVTGIAGTCL HHHHHHHHCCHHHHH | 19.81 | - | |
| 204 | Phosphorylation | RVTGIAGTCLALCLS HHHCCHHHHHHHHHC | 8.70 | - | |
| 211 | Phosphorylation | TCLALCLSSDLKSLS HHHHHHHCCCCCCCE | 22.32 | - | |
| 212 | Phosphorylation | CLALCLSSDLKSLSV HHHHHHCCCCCCCEE | 33.73 | - | |
| 256 | Phosphorylation | TRMARKFTHISALLQ HHHHHHHHHHHHHHH | 22.72 | 25072903 | |
| 259 | Phosphorylation | ARKFTHISALLQYIN HHHHHHHHHHHHHHH | 12.78 | 25072903 | |
| 264 | Phosphorylation | HISALLQYINLSLTC HHHHHHHHHHHHHHH | 7.55 | 25072903 | |
| 268 | Phosphorylation | LLQYINLSLTCMCEA HHHHHHHHHHHHHHH | 19.69 | 25072903 | |
| 270 | Phosphorylation | QYINLSLTCMCEAWE HHHHHHHHHHHHHHH | 8.53 | 25072903 | |
| 285 | Phosphorylation | EILMQMDSRLTKFVQ HHHHHCHHHHHHHHH | 24.69 | 25072903 | |
| 332 | Ubiquitination | LTVKGLKKLGQSIES CHHHHHHHHHHHHHH | 63.99 | - | |
| 332 | Ubiquitination | LTVKGLKKLGQSIES CHHHHHHHHHHHHHH | 63.99 | - | |
| 336 | Phosphorylation | GLKKLGQSIESSYSS HHHHHHHHHHHCCHH | 26.90 | 30622161 | |
| 339 | Phosphorylation | KLGQSIESSYSSIQK HHHHHHHHCCHHHHH | 32.67 | 30622161 | |
| 340 | Phosphorylation | LGQSIESSYSSIQKL HHHHHHHCCHHHHHH | 19.08 | 30622161 | |
| 341 | Phosphorylation | GQSIESSYSSIQKLV HHHHHHCCHHHHHHH | 18.73 | 30622161 | |
| 342 | Phosphorylation | QSIESSYSSIQKLVI HHHHHCCHHHHHHHH | 23.94 | 30622161 | |
| 343 | Phosphorylation | SIESSYSSIQKLVIS HHHHCCHHHHHHHHH | 22.32 | 30622161 | |
| 371 | Phosphorylation | SELKGMASWKQKYEP HHHCCCHHHHHHCCC | 26.39 | 24719451 | |
| 422 | Phosphorylation | KAFFRWLYVAMLRMT HHHHHHHHHHHHHHC | 4.53 | 29396449 | |
| 429 | Phosphorylation | YVAMLRMTEDHVLPE HHHHHHHCCCCCHHH | 31.65 | 21406692 | |
| 441 | Phosphorylation | LPELNKMTQKDITFV HHHHHHCCHHHHHHH | 33.79 | 27251275 | |
| 446 | Phosphorylation | KMTQKDITFVAEFLT HCCHHHHHHHHHHHH | 23.38 | 27251275 | |
| 468 | Ubiquitination | DLYNRKGKYFNVERV CHHHCCCCCCCHHHH | 50.10 | 21890473 | |
| 468 | Acetylation | DLYNRKGKYFNVERV CHHHCCCCCCCHHHH | 50.10 | 25953088 | |
| 468 (in isoform 1) | Ubiquitination | - | 50.10 | 21890473 | |
| 468 (in isoform 2) | Ubiquitination | - | 50.10 | 21890473 | |
| 469 | Phosphorylation | LYNRKGKYFNVERVG HHHCCCCCCCHHHHC | 14.73 | 22817900 | |
| 469 | Ubiquitination | LYNRKGKYFNVERVG HHHCCCCCCCHHHHC | 14.73 | - | |
| 478 | Phosphorylation | NVERVGQYLKDEDDD CHHHHCHHCCCCCCC | 15.13 | 22115753 | |
| 488 | Phosphorylation | DEDDDLVSPPNTEGN CCCCCCCCCCCCCCC | 41.77 | 22199227 | |
| 492 | Phosphorylation | DLVSPPNTEGNQWYD CCCCCCCCCCCHHHH | 51.55 | 22199227 | |
| 498 | Phosphorylation | NTEGNQWYDFLQNSS CCCCCHHHHHHHCCC | 6.25 | 28796482 | |
| 508 | Ubiquitination | LQNSSHLKESPLLFP HHCCCCCCCCCCCCC | 51.20 | - | |
| 510 | Phosphorylation | NSSHLKESPLLFPYY CCCCCCCCCCCCCCC | 21.18 | 28674419 | |
| 516 | Phosphorylation | ESPLLFPYYPRKSLH CCCCCCCCCCHHHHH | 20.83 | - | |
| 520 | Ubiquitination | LFPYYPRKSLHFVKR CCCCCCHHHHHHHHH | 53.52 | - | |
| 521 | Ubiquitination | FPYYPRKSLHFVKRR CCCCCHHHHHHHHHH | 28.49 | - | |
| 526 | Ubiquitination | RKSLHFVKRRMENII HHHHHHHHHHHHHHH | 33.09 | - | |
| 543 (in isoform 2) | Phosphorylation | - | 7.26 | 23090842 | |
| 625 | Phosphorylation | IKFGSFTYATTEKVR EEECCEEEECCHHHH | 10.43 | - | |
| 627 | Phosphorylation | FGSFTYATTEKVRRS ECCEEEECCHHHHHH | 25.69 | - | |
| 628 | Phosphorylation | GSFTYATTEKVRRSI CCEEEECCHHHHHHH | 26.15 | - | |
| 630 | Acetylation | FTYATTEKVRRSIYS EEEECCHHHHHHHHH | 38.66 | 7695573 | |
| 736 | Phosphorylation | KVSCVLSSNLRHVRV EEEEEEECCCCEEEE | 35.40 | 18452278 | |
| 757 | Phosphorylation | DEWELDESSDEEEEA CCCCCCCCCCHHHHH | 42.63 | 24260401 | |
| 758 | Phosphorylation | EWELDESSDEEEEAS CCCCCCCCCHHHHHH | 47.17 | 22496350 | |
| 765 | Phosphorylation | SDEEEEASNKPVKIK CCHHHHHHCCCCCCH | 48.98 | 27732954 | |
| 772 | Sumoylation | SNKPVKIKEEVLSES HCCCCCCHHHHHCHH | 41.95 | - | |
| 772 | Sumoylation | SNKPVKIKEEVLSES HCCCCCCHHHHHCHH | 41.95 | 28112733 | |
| 777 | Phosphorylation | KIKEEVLSESEAENQ CCHHHHHCHHHHHHH | 44.23 | 29255136 | |
| 779 | Phosphorylation | KEEVLSESEAENQQA HHHHHCHHHHHHHHH | 38.44 | 29255136 | |
| 798 | Sumoylation | LAPEIVIKVEKLDPE HCCEEEEEEEECCCC | 33.19 | 28112733 | |
| 798 | Sumoylation | LAPEIVIKVEKLDPE HCCEEEEEEEECCCC | 33.19 | - |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of APC4_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
| 468 | Ubiquitination | 465 (3) | R ⇒ Q;L | rs34811474 |
| 29326435 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-757 AND SER-758, ANDMASS SPECTROMETRY. | |
| "Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-777, AND MASSSPECTROMETRY. | |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-779, AND MASSSPECTROMETRY. | |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-777 AND SER-779, ANDMASS SPECTROMETRY. | |
| "Mitotic regulation of the human anaphase-promoting complex byphosphorylation."; Kraft C., Herzog F., Gieffers C., Mechtler K., Hagting A., Pines J.,Peters J.-M.; EMBO J. 22:6598-6609(2003). Cited for: PHOSPHORYLATION AT TYR-469 AND SER-779. | |
